The origins of their quarrel also started that year, when a unit of Novartis called Sandoz began working with another migraine company, the biotech Alder Biopharmaceuticals. Sandoz was manufacturing the experimental migraine drug ALD403 at a factory in Austria.
Amgen objected, and the two companies have been going back and forth about it since then. On Tuesday, Amgen gave Novartis notice that it wanted to terminate their collaboration.product to Aimovig and other, already-approved drugs from generic drugmaker Teva and pharma Eli Lilly. They all use a similar scientific approach to treating migraines preventatively, or before they happen.
The Swiss drug giant also says it's invested too much in Aimovig to get cut out now, having spent about $530 million to help out with the US launch last May. And though the companies haven't really disclosed how that breaks down, most assume they're roughly splitting profits, Mizuho analyst Salim Syed said.
We have to work on a surgical fix for migranes. This is scar tissue from a tramatic injury causing blockage. A structural weakness in the vascular system. Maybe a stint fix. Patch it.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »
Source: CNBC - 🏆 12. / 72 Read more »